The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1
Open accessAbstract
Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly population. Accumulation, aggregation, and deposition of amyloid-β (Aβ) peptides generated through proteolytic cleavage of amyloid precursor protein (APP) are likely initiating events in the pathogenesis of AD. While Aβ production is accelerated in familial AD, increasing evidence indicates that impaired clearance of Aβ is responsible for late-onset AD. Because Aβ is mainly generated in neurons, these cells are predicted to have the highest risk of encountering Aβ among all cell types in the brain. However, it is still unclear whether they are also involved in Aβ clearance. Here we show that receptor-mediated endocytosis in neurons by the low-density lipoprotein receptor-related protein 1 (LRP1) plays a critical role in brain Aβ clearance. LRP1 is known to be an endocytic receptor for multiple ligands including Aβ. Conditional knock-out of Lrp1 in mouse forebrain neurons leads to increased brain Aβ levels and exacerbated amyloid plaque deposition selectively in the cortex of amyloid model APP/PS1 mice without affecting Aβ production.In vivo microdialysis studies demonstrated that Aβ clearance in brain interstitial fluid is impaired in neuronal Lrp1 knock-out mice. Because the neuronal LRP1-deletion did not affect the mRNA levels of major Aβ degrading enzymes, neprilysin and insulin-degrading enzyme, the disturbed Aβ clearance is likely due to the suppression of LRP1-mediated neuronal Aβ uptake and degradation. Together, our results demonstrate that LRP1 plays an important role in receptor-mediated clearance of Aβ and indicate that neurons not only produce but also clear Aβ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have shown that the bulk of soluble Aβ is cleared through its direct interaction with the LDL receptor family expressed by brain capillary endothelium [37], neurons [24,38], and astrocytes [39,40], therefore pharmacological disruption of the apoE/Aβ binding is unlikely to impair this process.”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Collectively, these recent findings underscore the influence of APOE and APOE3Ch on both Aβ and tau pathology, either directly or through downstream effects such as neuroinflammation.”
From APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies indicate that APOE binding is integral to some of these processes [16–20] with differences in APOE isoform-specific receptor binding affinity and lipid interactions affecting neuroinflammation, tau pathology, and amyloid plaque dynamics [21–24].”
From APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Receptors such as LRP1 can regulate APP endocytosis and amyloidogenic processing while also mediating cellular uptake and clearance of extracellular Aβ (Kanekiyo and Bu, 2014; Kanekiyo et al., 2013; Van Gool et al., 2019).”
From Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch (2026) · cites this paper as Kanekiyo et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 mediates and regulates the endocytosis of > 30 ligands, including apolipoprotein E (APOE) and amyloid-β (Aβ) [21–27]”
From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [22]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Although there are additional methods of Aβ clearance (6, 7, 38, 39), our and other data show that vascular transport across the BBB is of crucial importance for rapid Aβ elimination from brain (8,11,15).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Genome-wide atlas of gene expression in the adult mouse brain
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A. F., Boguski, M. S., Brockway, K. S., Byrnes, E. J., et al. (2007) · Nature · doi:10.1038/nature05453 · Cited by 5,572
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Self-citationSynaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265
Self-citationApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Self-citationBorchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Adult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
LRP: a multifunctional scavenger and signaling receptor
Herz, J., & Strickland, D. K. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13992 · Cited by 908
Cited by
Sorted by citations
Items 201–282 of 282
Association between LRP1 C766T polymorphism and Alzheimer’s disease susceptibility: a meta-analysis
Wang, Y., Liu, S., Wang, J., Zhang, J., Hua, Y., Li, H. L., Tan, H., Kuai, B., Wang, B., & Sheng, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-08335-w · Cited by 11
Klotho: molecular mechanisms and emerging therapeutics in central nervous system diseases
Hosseini, L., Babaie, S., Shahabi, P., Fekri, K., Shafiee‐Kandjani, A. R., Mafikandi, V., Maghsoumi‐Norouzabad, L., & Abolhasanpour, N. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09862-2 · Cited by 11
Widespread transposable element dysregulation in human aging brains with Alzheimer's disease
Feng, Y., Yang, X. J., Hou, Y., Zhou, Y., Leverenz, J. B., Eng, C., Pieper, A. A., Goate, A., Shen, Y., & Cheng, F. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14164 · Cited by 11
Biomarker changes associated with fornix deep brain stimulation in Alzheimer's disease
Germann, J., Amaral, R. S. C., Tomaszczyk, J. C., Yamamoto, K., Elias, G. J. B., Gouveia, F. V., Vasilevskaya, A., Taghdiri, F., Devenyi, G. A., Sankar, T., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70394 · Cited by 11
Neuropathological links between T2DM and LOAD: systematic review and meta-analysis
Lemche, E., Hortobágyi, T., Kiecker, C. M., & Turkheimer, F. (2025) · Physiological Reviews · doi:10.1152/physrev.00040.2024 · Cited by 9
Shanmugam, N. K. N., Zamudio, F., Kumar, D. K. V., Barrett, K. A., VanDoren, R., Chen, M., Barr, O. M., Watson, S., Lin, C., Eimer, W. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70292 · Cited by 8
DKK3-LRP1 complex and a chemical inhibitor regulate Aβ clearance in models of Alzheimer’s disease
Yang, R., Wang, L., Li, Y., Zhu, J., Wang, J., Schlessinger, D., & Sima, J. (2025) · Science Advances · doi:10.1126/sciadv.adz2099 · Cited by 8
Diversified Control Paths: A Significant Way Disease Genes Perturb the Human Regulatory Network
Wang, B., Gao, L., Zhang, Q., Li, A., Deng, Y., & Guo, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135491 · Cited by 8
Au, D. T., Arai, A. L., Fondrie, W. E., Muratoglu, S. C., & Strickland, D. K. (2018) · Current Drug Targets · doi:10.2174/1389450119666180511162048 · Cited by 9
Breuza, L., Arighi, C. N., Argoud‐Puy, G., Casals‐Casas, C., Estreicher, A., Famiglietti, M. L., Georghiou, G. P., Gos, A., Gruaz-Gumowski, N., Hinz, U. G., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200206 · Cited by 8
Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease
Hone, E., Lim, F., & Martins, I. J. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch7 · Cited by 8
The glycosaminoglycan chains of perlecan regulate the perivascular fluid transport
Singh, A., Kaakinen, M., Elamaa, H., Kiviniemi, V. J., & Eklund, L. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00648-7 · Cited by 7
Ebrahimi, R., Bordbar, S., Azad, G., Davoody, S., Mahmoudi, M., & Esmaeilpour, K. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08403-4 · Cited by 8
Systems-level organization of extracellular proteostasis
Gomes, C. M., & Vendruscolo, M. (2026) · Science · doi:10.1126/science.aed3712 · Cited by 8
Wang, R., Xu, Z., Li, Y., Li, W., Gao, X.-R., Liu, C., & Liu, C. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104644 · Cited by 7
Self-citationUnni, P. A., Pillai, G. G., & Sajithalulu, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119079 · Cited by 7
Olejár, T., Jankovská, N., & Matěj, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179689 · Cited by 6
Rai, A., Ojiakor, O. A., & Rylett, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15904 · Cited by 6
Tsai, Y.-C., Luo, J.-C., Liu, T., Lu, I.-L., Shen, M., Chuang, C., Chern, C., & Chiu, H. (2020) · Nanomaterials · doi:10.3390/nano10071284 · Cited by 6
Apolipoprotein E and Amyloid-β-Independent Mechanisms in Alzheimer’s Disease
Kanekiyo, T., & Bu, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00006-1 · Cited by 6
Self-citationLachén‐Montes, M., Íñigo-Marco, I., Cartas‐Cejudo, P., Fernández‐Irigoyen, J., & Santamaría, E. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060503 · Cited by 6
Sena, P. P., Friedrich, L., Villarreal, A. E., Fath, F., Sopco, L., Hernández‐Guillamón, M., Pereira, M. L. S., Britton, G. B., Weber, J. J., & Schmidt, T. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1681079 · Cited by 6
Xiong, C., Tang, Y., Chen, J., Fan, M., Wei, L., Dong, Z., Lai, X., Men, X., Chen, Q., Li, D., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00512-6 · Cited by 6
Guardians of homeostasis: Natural products target metabolic reprogramming in Alzheimer’s disease
Zhang, Z., Xu, H., Zhao, F., Han, Z., Pan, J., Li, M., Guan, W., Jiang, P., Hao, Z., Zhang, Y., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.103005 · Cited by 5
Huang, N., Hong, R., Cui, X., Cao, L., Shi, L., Chen, B., Su, Y., Xu, X., Hua, C., & Ying, T. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04297-2 · Cited by 5
Insulin-like peptides signaling in Alzheimer's disease: on the road to alternative therapeutics
Trueba-Sáiz, Á., & Torres‐Alemán, I. (2015) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2015.11.013 · Cited by 5
Saleh, O. M., Albakri, K. A., Altiti, A., Abutair, I., Shalan, S. S., Mohd, O. B., Negida, A., Mushtaq, G., & Kamal, M. A. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230519113201 · Cited by 5
Xu, Z., Huang, H., Chen, Y., Gao, Y.-Y., Xu, J., Marshall, C., Cai, Z., & Xiao, M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150634 · Cited by 5
The role of amyloid beta 4-42 in the etiology of Alzheimer's disease
Bouter, Y. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4849 · Cited by 5
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 5
Yéfimova, M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355753 · Cited by 4
Peroxisomes in intracellular cholesterol transport: from basic physiology to brain pathology
Xiao, J., Song, B., & Luo, J. (2021) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2021.00011 · Cited by 4
Lipids and Lipoproteins in Alzheimer’s Disease
Stukas, S. K., Kulić, I., Zareyan, S., & Wellington, C. L. (2015) · InTech eBooks · doi:10.5772/59808 · Cited by 5
Endothelial LRP1 activation mitigates microthrombosis after traumatic brain injury in mice
Yan, R., Wang, J., Wu, J., Qiu, X., Yang, L., Yang, J., Jiang, Y. D., & Peng, J. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115324 · Cited by 3
Vitamin D in Alzheimer's disease: Neuroinflammatory, metabolic, and clinical implications
Kashif, M., Ho, M.-H., Pandurangan, A. K., Waseem, M., Majumder, D., & Chou, S. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261460850 · Cited by 4
LRP1 regulates asthmatic airway smooth muscle proliferation through FGF2/ERK signaling
Deng, Y., Zhao, J., Chen, G., Ding, W., Fang, L., Liu, H., Li, M., Shen, B. Q., & Ding, S. (2025) · JCI Insight · doi:10.1172/jci.insight.185975 · Cited by 3
Cordi, C. V., & Hurley, J. (2025) · Current Opinion in Physiology · doi:10.1016/j.cophys.2025.100859 · Cited by 3
Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
Patel, K., Srivastava, S., Kushwah, S., & Mani, A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210027 · Cited by 4
Rozeboom, A., Broekaart, D. W. M., Anink, J. J., Boonkamp, L., Idema, S., Teunissen, C. E., Aronica, E., Gorter, J. A., & van Vliet, E. A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115149 · Cited by 2
Yata, V. K., Das, O. P., Dansana, J., Gadtya, A., Meher, B. R., Bukke, S. P. N., & Kolliputi, N. (2025) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2025.1709505 · Cited by 2
Zhou, T., Zhang, R., Ohulchanskyy, T. Y., & Qu, J. (2025) · Biomedical Optics Express · doi:10.1364/boe.549594 · Cited by 2
Neuro-pathological Implications of β-Amyloid Protein: An Update
Maurya, N., & Agarwal, N. R. (2018) · Proceedings of the Nature Research Society · doi:10.11605/j.pnrs.2018020061 · Cited by 2
Yang, R., Li, Y., Zhao, X., Wang, L., Wu, J., & Sima, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.08.663694 · Cited by 3
Profiling of the Proteins Interacting with Amyloid Beta Peptides in Clinical Samples by PACTS-TPP
Xu, M., Wang, X., Zhang, Y., Ji, N., Wang, Q., Zhao, T., Zhou, C., & Jia, C. (2024) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.4c00083 · Cited by 2
The Proteome of Human Amyloid Beta Oligomers
Kass, B., Poschmann, G., Demir, F., Huesgen, P. F., Stühler, K., Kutzsche, J., & Willbold, D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00597 · Cited by 1
Guo, H., Peng, X., Zhang, X. C., Ruganzu, J. B., Wu, X., Zhao, M., Pengbo, Y., Ji, S., & Yang, W. (2026) · Experimental Cell Research · doi:10.1016/j.yexcr.2026.114920 · Cited by 1
Sambhariya, W. S., Rickman, C. B., D'Amore, P. A., Corradetti, G., Hageman, G. S., Howell, G. R., Marola, O. J., Phatnani, H. P., Philp, N. J., Sinha, D., et al. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101449 · Cited by 1
Targeting Wnt signaling in Alzheimer’s disease: mechanisms and therapeutic opportunities
Zhao, X., Yang, R., Wu, J., & Sima, J. (2026) · Aging Research · doi:10.26599/agr.2026.9340068 · Cited by 1
Is amyloid beta peptide a driver of inflammaging?
Kechko, O. I., Moskalev, A. A., Franceschi, C., Mitkevich, V. A., & Makarov, A. А. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103280 · Cited by 1
Stephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1
A human embryonic stem cell model of Aβ-dependent chronic progressive neurodegenerationPreprint
Ubina, T., Magallanes, M., Srivastava, S., Warden, C., Yee, J., & Salvaterra, P. M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/419978 · Cited by 1
Azmoon, P., Mantuano, E., Poudel, B., Zampieri, C., & Gonias, S. L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.06.561299 · Cited by 1
Endocytosis at the mouse blood brain barrier is elevated during sleepPreprint
Li, F., Chen, D., & Sehgal, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.02.716170 · Cited by 1
Frisch, C., Baker, L., Srinivasan, G., Mintah, A. E., Leyasi, S., Pedroza, M., Galyon, B., & Brafman, D. A. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1856154
Hettinger, J. C. (2017) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7jq10fn
Investigating the functional roles of microRNA-29b and microRNA-146a in prion diseases
Zhao, W. (2018) · Minerva Access (University of Melbourne)
Amyloid beta inducerad klyvning av NG2 medierad via LRP-1 receptorn
Hallberg, A. (2014) · Malmö University Publications (Malmö University)
ApoE Receptors, Molecular Processes, and Cellular Signaling Pathways
Jaeschke, A., & Hui, D. Y. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_6-1
MEGF10 knockout promotes cortical and hippocampal amyloid deposition in AD mouse model
Fujita, Y., Yabe, T., Yamada, Y., Kiuchi, R., Nagase, M., Nakamori, R., Ichikawa, S., Obara, T., Yasuda, H., Kurano, J., et al. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138487
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26614915
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26614924
Su, Q., Li, T., He, P.-F., Lu, X.-C., Yu, Q., Gao, Q.-C., Wang, Z., Wu, M.-N., Yang, D., & 祁金顺 (2021) · Figshare · doi:10.6084/m9.figshare.13520737
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26614909
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26614918
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26614921
Additional file 1 of LRP1 is a neuronal receptor for α-synuclein uptake and spread
Chen, K., Martens, Y. A., Meneses, A. D., Ryu, D. H., Lü, W., Raulin, A. C., Li, F., Zhao, J., Chen, Y., Jin, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20861097
Self-citationJang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26614927
Additional file 1 of Synaptic tau: A pathological or physiological phenomenon?
Robbins, M., Clayton, E. L., & Schierle, G. S. K. (2021) · Figshare · doi:10.6084/m9.figshare.16599510
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26614906
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26614912
Cerebral amyloid angiopathy: updates on pathophysiology, diagnosis, and management
Willsey, T. R., Faselis, C. J., Ahmed, A., & Sin, M. (2026) · Exploration of neuroscience · doi:10.37349/en.2026.1006121
The Role of ApoE Genetics in Glial Lipid Metabolism and Inflammation
Julia, T. C. W., Negi, R., & Kurkela, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_74-1
Molecular mechanisms of action of MT-MMPs involved in the pathogenesis of Alzheimer’s disease
García‐González, L. (2020) · theses.fr (ABES) · doi:10.70675/a04672c0z1f4az472ezbcd5zbea446eac50c
The Role of ApoE Genetics in Glial Lipid Metabolism and Inflammation
Julia, T. C. W., Negi, R., & Kurkela, M. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_74
Neurovascular coupling and energy substrate delivery in Alzheimer’s disease
Malviya, S., Saha, D., Kamble, A., Singh, D. R., Sundaram, S. M., & Devanathan, V. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.001
Czaniera, N. J., Schulten, W., Nowak, K., Pschik, D., Joneleit, J., Kaltschmidt, B., & Kaltschmidt, C. (2026) · Cells · doi:10.3390/cells15121057
Li, Q., Liu, X., Xing, R., Qi, F., Li, X., Wang, K., & Chen, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118188
Chandrashekar, D. V., Roules, G. C., Panchal, U. R., Jagadeesan, N., Newhart, C., Chu, J., Carson, B., Win, S., Than, T. A., Kaplowitz, N., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10843451/v1
Metadata
- Authors
- Kanekiyo, T., Cirrito, J. R., Liu, C.-C., Shinohara, M., Li, J., Schuler, D. R., Shinohara, M., Holtzman, D. M., & Bu, G.
- Affiliations
- Mayo Clinic (US)
- Washington University in St. Louis (US)
- ORCID
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2013-12-04
- Volume
- 33
- Issue
- 49
- Pages
- 19276-19283
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC3850043
- OpenAlex
- W2084969119
- Cited by
- 280
- References
- 40
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 25 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 29 · 2019: 24 · 2018: 19 · 2017: 20 · 2016: 21 · 2015: 23 · 2014: 17
- FWCI
- 14.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (P01AG030128, P50‐AG16574, R01AG027924, R37AG13956, R01AG042513, RF1AG046205, R01AG046205, R37AG013956, R01AG035355, P50AG016574)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- amyloid-beta clearance, LRP1, Alzheimer's disease, receptor-mediated endocytosis, neurons, amyloid plaques, APP/PS1 mice, brain interstitial fluid, neprilysin, insulin-degrading enzyme, amyloid precursor protein, conditional knockout mice
- MeSH terms
- Animals, Cerebral Cortex, Enzyme-Linked Immunosorbent Assay, Hippocampus, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Neurons, Receptors, LDL, RNA, Messenger, Blotting, Western, Polymerase Chain Reaction, Amyloid beta-Peptides, Mice, Knockout, Microscopy, Confocal, Transport Vesicles, Tumor Suppressor Proteins, Low Density Lipoprotein Receptor-Related Protein-1, RNA, Small Interfering, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
